



# Programme

**Tuesday, 5 March 2024**

## CONFERENCE ROOM

16:30-16:45

**When to use adjuvant or neoadjuvant therapy in  
locoregional melanoma?**

*Piotr Rutkowski*

16:45-17:00

**When to use combined immunotherapy (ipilimumab and  
nivolumab or nivolumab and relatlimab) or anti-PD-1  
monotherapy in treatment of advanced melanomas?**

*Mario Mandala*

17:00-17:15

**Current role of BRAF and MEK inhibitors**

*Katarzyna Kozak*

17:15-17:25

**Discussion**

17:25-17:55

**Challenging cases**

17:25-17:35

Case report under the patronage of Pierre Fabre Medicament: Long  
responders after encorafenib and binimetinib treatment in BRAF  
V600 advanced melanoma patients

*Anna M. Czarnecka*

17:35-17:45

Choice of I line treatment after progression during adjuvant  
therapy

*Alice Indini*

17:45-17:55

Case report under the patronage of MSD: The importance of  
adjuvant immunotherapy in stage III melanoma

*Anna M. Czarnecka*

Patronage



Organizer



Media Patronage



Partner

